Filing Flows › Companies › Sanofi › Timeline
Sanofi stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions+0.3% to $47.04
Sanofi (SNY) stock rose 0% over the last 252 sessions, to $47.04. On the way it reported 4 quarters, its insiders filed no open-market trades (10b5-1 plan sales aside), and the company filed 0 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Oct 30, 2026 | Earnings | Earnings: beat the EPS estimate by 31.2% | +2.8% (+4.6% vs SPY) | +8.4% (+13.2% vs SPY) | — |
| Jul 30, 2026 | Earnings | Earnings: beat the EPS estimate by 5.6% | −4.5% (−6.1% vs SPY) | −4.7% (−10.1% vs SPY) | 0.0% (−5.6% vs SPY) |
| Apr 23, 2026 | Earnings | Earnings: beat the EPS estimate by 7.3% | +1.3% (+1.7% vs SPY) | −1.9% (−1.9% vs SPY) | +1.1% (−3.3% vs SPY) |
| Jan 29, 2026 | Earnings | Earnings: beat the EPS estimate by 7.4% | +0.9% (+1.1% vs SPY) | +4.9% (+6.3% vs SPY) | +6.1% (+7.5% vs SPY) |
Report card: every quarter against the estimate → Sanofi: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.